Veru Inc Q3 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Congratulations on all the progress during the quarter. Firstly, on 111, when we see the Phase Ib data presented in September, will there be any new data? And if so, what do you think are going to be the most pertinent part of the data we see from that Ib, given that we've seen some of it, later in the year? And then secondly, just as a follow-on, on -- staying on 111, I think -- as you've spoken in the past, you've talked about having a very good indication of what you believe the FDA wants to see from a Phase III protocol and it sounds like that's been further confirmed with the dialogue. But maybe just as the Phase II progresses, do you envision any amendments to the Phase III protocol? And what are some of the factors there that you're watching in the Phase II that could still meaningfully affect the Phase III protocol?

Question: Brandon Richard Folkes - Cantor Fitzgerald & Co., Research Division - Analyst : Great. It's very comprehensive. Look forward to seeing the data in September. Maybe just one more, if I can sneak in and I'll hop back in the queue. On the COVID program, if you succeed from the Phase II, do you think there's a chance of getting emergency use authorization for that product?